Monoclonal Antibodies for Targeted Fluorescence-Guided Surgery: A Review of Applicability across Multiple Solid Tumors.
Loading...
Embargo End Date
ICR Authors
Authors
Giuliani, S
Paraboschi, I
McNair, A
Smith, M
Rankin, KS
Elson, DS
Paleri, V
Leff, D
Stasiuk, G
Anderson, J
Precision Surgery Group at the NIHR Oncology Translational Research Collaboration,
Paraboschi, I
McNair, A
Smith, M
Rankin, KS
Elson, DS
Paleri, V
Leff, D
Stasiuk, G
Anderson, J
Precision Surgery Group at the NIHR Oncology Translational Research Collaboration,
Document Type
Journal Article
Date
2024-03-04
Date Accepted
2024-02-28
Abstract
This study aims to review the status of the clinical use of monoclonal antibodies (mAbs) that have completed or are in ongoing clinical trials for targeted fluorescence-guided surgery (T-FGS) for the intraoperative identification of the tumor margins of extra-hematological solid tumors. For each of them, the targeted antigen, the mAb generic/commercial name and format, and clinical indications are presented, together with utility, doses, and the timing of administration. Based on the current scientific evidence in humans, the top three mAbs that could be prepared in a GMP-compliant bank ready to be delivered for surgical purposes are proposed to speed up the translation to the operating room and produce a few readily available "off-the-shelf" injectable fluorescent probes for safer and more effective solid tumor resection.
Citation
Cancers, 2024, 16 (5), pp. 1045 -
Source Title
Cancers
Publisher
MDPI
ISSN
2072-6694
eISSN
2072-6694
2072-6694
2072-6694
Collections
Research Team
Translational Sarcoma, Melanoma and Rare Tumour Surgery